Immunovant (IMVT) news
Recent news
Immunovant: cash and cash equivalents total $797.80 mln as of June 30, 2026
Immunovant, Inc. (Nasdaq: IMVT) reported its financial results for the quarter ended March 31, 2026, revealing total of $902.1 million in cash and cash equivalents as of that date. This figure indicates a significant increase compared to the $713.97 million reported as of March 31, 2025. The…
AInvest Wire · Aug 6, 2026ImportantImmunovant shares gain 21% after fourth quarter results
AInvest Wire · May 20, 2026Immunovant 4Q loss/share 73c vs. loss/share 64c y/y
Immunovant, Inc. (Nasdaq: IMVT) reported a net loss of $0.73 per share for the fourth quarter of fiscal 2025, representing an increase from $0.64 per share loss in the same period of the prior year. The company’s financial performance reflects continued investment in its clinical-stage pipeline,…
AInvest Wire · May 20, 2026Immunovant 4Q loss before provision for income taxes $150.7M
AInvest Wire · May 20, 2026ImportantImmunovant Shares Rise 9% After Positive Data From Graves' Disease Treatment Trial
Immunovant Shares Rise 9% After Positive Data From Graves' Disease Treatment Trial Immunovant, a clinical-stage immunology company, recently announced positive data from its ongoing 24-week Phase 2 clinical trial for its batoclimab treatment for Graves' disease [1][2][3]. The trial results showed…
AInvest Wire · Dec 21, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.